These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 18931861

  • 21. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia.
    Kotasek D, Canon JL, Mateos MV, Hedenus M, Rossi G, Taylor K.
    Curr Med Res Opin; 2007 Jun; 23(6):1387-401. PubMed ID: 17559735
    [Abstract] [Full Text] [Related]

  • 22. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.
    Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
    [Abstract] [Full Text] [Related]

  • 23. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD, Kolmakova E, Fung M, Malecki R, Vinhas J, Dellanna F, Thomas M, Manamley N, Ferenczi S.
    Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.
    Bustos A, Álvarez R, Aramburo PM, Carabantes F, Díaz N, Florián J, Lázaro M, de Segovia JM, Gasquet JA, Alegre A, RADAR Study Group.
    Curr Med Res Opin; 2012 Jan; 28(1):57-67. PubMed ID: 22070513
    [Abstract] [Full Text] [Related]

  • 26. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Bastit L, Vandebroek A, Altintas S, Gaede B, Pintér T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF.
    J Clin Oncol; 2008 Apr 01; 26(10):1611-8. PubMed ID: 18375890
    [Abstract] [Full Text] [Related]

  • 27. Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy - data from the CHOICE study.
    Van Belle S, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B.
    Curr Med Res Opin; 2011 May 01; 27(5):987-94. PubMed ID: 21385113
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia.
    Boccia RV, Henry DH, Belton L, Bohac C, Ghazal HH.
    Cancer Med; 2016 Dec 01; 5(12):3445-3453. PubMed ID: 27882724
    [Abstract] [Full Text] [Related]

  • 29. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Dec 01; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia.
    Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson DM, Mattar BI, Moore DF, Nikcevich D, Loprinzi CL.
    Am J Hematol; 2015 Oct 01; 90(10):877-81. PubMed ID: 26149465
    [Abstract] [Full Text] [Related]

  • 33. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun 01; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia.
    Polsky D, Eremina D, Hess G, Hill J, Hulnick S, Roumm A, Whyte JL, Kallich J.
    Pharmacoeconomics; 2009 Jun 01; 27(9):755-65. PubMed ID: 19757869
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R) CHOP.
    Pettengell R, Silvestre AS, Schwenkglenks M, Rossi FG, Duehrsen U, Verhoef G, Lugtenburg PJ, Wheeler T, Pujol B, Haioun C.
    Hematology; 2013 Jan 01; 18(1):26-9. PubMed ID: 22980138
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.